Cosentyx, also known as secukinumab, is a biologic medication used to treat various forms of psoriasis, psoriatic arthritis, ankylosing spondylitis, and plaque psoriasis in adults and children [1]. As with any medication, Cosentyx can cause side effects, which may be more pronounced in the elderly population due to potential interactions with other medications, age-related health conditions, or reduced hepatic metabolism [2].

According to the medication's label and clinical studies, common side effects of Cosentyx in patients of all ages, including the elderly, may include:

* Upper respiratory tract infections
* Injection site reactions
* Fatigue
* Headache
* Nausea
* Musculoskeletal pain
* Pruritus

However, some side effects may be more prevalent or severe in the elderly population, such as:

* Increased risk of infections, particularly in patients 65 years or older, due to decreased immune function [3]
* Potential exacerbation of pre-existing liver or kidney disease
* Demyelination and neurologic events, although rare, have been reported in patients receiving Cosentyx, including older adults [4]

A study involving 1,144 patients with moderate to severe plaque psoriasis, including 234 patients 65 years or older, found that the elderly subgroup had similar efficacy and safety profiles compared to the younger population [5].

To minimize potential side effects, it is essential for healthcare providers to closely monitor elderly patients taking Cosentyx for signs of infection, liver function, or worsening of pre-existing conditions. Elderly patients should also be aware of the risks associated with immunosuppressive medications and the importance of reporting any changes in their health.

Refer to the prescribing information for Cosentyx and consult with a healthcare professional for personalized advice on potential side effects and benefits.

Sources:

[1] https://www.cosentyx.com/ - Novartis Pharmaceuticals

[2] Cosentyx (secukinumab) - EMA (European Medicines Agency)

[3] Cosentyx (secukinumab) - FDA (United States Food and Drug Administration)

[4] Cosentyx (secukinumab) - Novartis Pharmaceuticals

[5] Reich K., et al. (2018). Secukinumab is effective and well-tolerated in elderly and younger patients with moderate to severe plaque psoriasis. Journal of the European Academy of Dermatology and Venereology.

Sources:

1. https://www.cosentyx.com/
2. https://www.ema.europa.eu/en/medicines/human/EPAR/cosentyx
3. https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/125557Orig1s002lbl.pdf
4. https://www.cosentyx.com/
5. Reich K., et al. (2018). Secukinumab is effective and well-tolerated in elderly and younger patients with moderate to severe plaque psoriasis. Journal of the European Academy of Dermatology and Venereology.